Venous Thromboembolism (VTE) in Cancer Patients;a Multicenter Prospective Registry
Not Applicable
- Conditions
- colon cancer, lung cancer, gastric cancer, breast cancer, gynecologic cancer, pancreatic cancer
- Registration Number
- JPRN-UMIN000024942
- Lead Sponsor
- Medical Science Department Daiichi Sankyo Company, Limited.
- Brief Summary
The cumulative incidences of symptomatic VTE, bleeding, and all-cause death one year after enrollment were 0.5%, 1.4%, and 12.2%, respectively. Symptomatic VTE was more common in patients with pancreatic cancer and patients with Stage IV disease regardless of cancer type. Patients with VTE before initiation of cancer treatment, even asymptomatic distal DVT, had a higher risk of subsequent symptomatic VTE, bleeding, and all-cause death.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10202
Inclusion Criteria
Not provided
Exclusion Criteria
A patient who is inappropriate as a subject of the study judged by investigator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (1)Baseline frequency of intercurrent of VTE at the time of VTE screening (2)Observation period (one year) incidence of symptomatic VTE incidence of bleeding events
- Secondary Outcome Measures
Name Time Method Incidence of brain infarction/ systemic embolism Survival VTE related mortality rate and bleeding related mortality rate Brain infarction related mortality rate and systemic embolism related mortality rate